drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00808 | DB11057 | 1,605 | 720 | [
"DDInter916",
"DDInter1223"
] | Indapamide | Mineral oil | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1605,
24,
720
]
],
[
[
1605,
63,
175
],
[
175,
24,
720
]
],
[
[
1605,
24,
1486
],
[
1486,
24,
720
]
],
[
[
1605,
40,
811
],
[
811,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Methylpredniso... |
DB00564 | DB00835 | 1,236 | 100 | [
"DDInter293",
"DDInter245"
] | Carbamazepine | Brompheniramine | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1236,
24,
100
]
],
[
[
1236,
24,
832
],
[
832,
24,
100
]
],
[
[
1236,
40,
508
],
[
508,
24,
100
]
],
[
[
1236,
63,
128
],
[
128,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Carbamazepine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate inter... |
DB00008 | DB01156 | 491 | 593 | [
"DDInter1407",
"DDInter252"
] | Peginterferon alfa-2a | Bupropion | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
491,
25,
593
]
],
[
[
491,
24,
996
],
[
996,
63,
593
]
],
[
[
491,
24,
126
],
[
126,
24,
593
]
],
[
[
491,
23,
450
],
[
450,
24,... | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
],
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00048 | DB00682 | 1,595 | 126 | [
"DDInter435",
"DDInter1951"
] | Collagenase clostridium histolyticum | Warfarin | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1595,
24,
126
]
],
[
[
1595,
24,
477
],
[
477,
62,
126
]
],
[
[
1595,
24,
885
],
[
885,
63,
126
]
],
[
[
1595,
24,
1018
],
[
1018,
... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Warfarin
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbat... |
DB00366 | DB01069 | 1,594 | 401 | [
"DDInter600",
"DDInter1533"
] | Doxylamine | Promethazine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1594,
24,
401
]
],
[
[
1594,
24,
146
],
[
146,
24,
401
]
],
[
[
1594,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1594,
40,
939
],
[
939,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Dox... |
DB11730 | DB15822 | 351 | 69 | [
"DDInter1588",
"DDInter1504"
] | Ribociclib | Pralsetinib | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
351,
24,
69
]
],
[
[
351,
23,
283
],
[
283,
24,
69
]
],
[
[
351,
63,
1446
],
[
1446,
24,
69
]
],
[
[
351,
64,
1213
],
[
1213,
24... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
... | Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreot... |
DB01072 | DB12332 | 915 | 1,619 | [
"DDInter129",
"DDInter1626"
] | Atazanavir | Rucaparib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
915,
24,
1619
]
],
[
[
915,
25,
1135
],
[
1135,
23,
1619
]
],
[
[
915,
24,
309
],
[
309,
24,
1619
]
],
[
[
915,
63,
1419
],
[
1419,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Atazanavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a m... |
DB00056 | DB09054 | 816 | 384 | [
"DDInter814",
"DDInter905"
] | Gemtuzumab ozogamicin | Idelalisib | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
816,
24,
384
]
],
[
[
816,
24,
1627
],
[
1627,
62,
384
]
],
[
[
816,
24,
58
],
[
58,
24,
384
]
],
[
[
816,
63,
305
],
[
305,
24,... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canna... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB08886 | DB11767 | 637 | 1,583 | [
"DDInter126",
"DDInter1643"
] | Asparaginase Erwinia chrysanthemi | Sarilumab | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
637,
24,
1583
]
],
[
[
637,
63,
267
],
[
267,
24,
1583
]
],
[
[
637,
24,
713
],
[
713,
24,
1583
]
],
[
[
637,
64,
1510
],
[
1510,
... | [
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate d... |
DB00092 | DB09237 | 58 | 1,586 | [
"DDInter40",
"DDInter1045"
] | Alefacept | Levamlodipine | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
58,
24,
1586
]
],
[
[
58,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
58,
24,
870
],
[
870,
24,
1586
]
],
[
[
58,
24,
405
],
[
405,
63... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone an... |
DB01222 | DB14975 | 617 | 988 | [
"DDInter246",
"DDInter1949"
] | Budesonide | Voxelotor | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
617,
24,
988
]
],
[
[
617,
40,
251
],
[
251,
24,
988
]
],
[
[
617,
63,
629
],
[
629,
24,
988
]
],
[
[
617,
24,
578
],
[
578,
24,... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a mo... | Budesonide (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that co... |
DB09128 | DB14723 | 1,241 | 159 | [
"DDInter231",
"DDInter1026"
] | Brexpiprazole | Larotrectinib | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1241,
24,
159
]
],
[
[
1241,
63,
222
],
[
222,
23,
159
]
],
[
[
1241,
24,
741
],
[
741,
24,
159
]
],
[
[
1241,
63,
98
],
[
98,
2... | [
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]... | Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant a... |
DB00812 | DB12267 | 998 | 1,476 | [
"DDInter1451",
"DDInter233"
] | Phenylbutazone | Brigatinib | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
998,
24,
1476
]
],
[
[
998,
24,
1135
],
[
1135,
23,
1476
]
],
[
[
998,
62,
168
],
[
168,
23,
1476
]
],
[
[
998,
25,
629
],
[
629,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bort... |
DB00357 | DB00980 | 1,051 | 969 | [
"DDInter71",
"DDInter1564"
] | Aminoglutethimide | Ramelteon | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
1051,
24,
969
]
],
[
[
1051,
6,
7950
],
[
7950,
45,
969
]
],
[
[
1051,
21,
28921
],
[
28921,
60,
969
]
],
[
[
1051,
23,
1144
],
[
1144... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v}... | Aminoglutethimide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ramelteon (Compound)
Aminoglutethimide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ramelteon (Compound)
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Na... |
DB00867 | DB08871 | 1,052 | 36 | [
"DDInter1606",
"DDInter666"
] | Ritodrine | Eribulin | Adrenergic beta-agonist used to control premature labor. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1052,
24,
36
]
],
[
[
1052,
63,
1424
],
[
1424,
24,
36
]
],
[
[
1052,
24,
609
],
[
609,
24,
36
]
],
[
[
1052,
24,
971
],
[
971,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Qu... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromyc... |
DB00342 | DB09080 | 1,181 | 144 | [
"DDInter1770",
"DDInter1331"
] | Terfenadine | Olodaterol | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1181,
24,
144
]
],
[
[
1181,
23,
1247
],
[
1247,
23,
144
]
],
[
[
1181,
24,
956
],
[
956,
24,
144
]
],
[
[
1181,
25,
1011
],
[
1011,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin... |
DB00976 | DB08875 | 1,056 | 1,618 | [
"DDInter1758",
"DDInter262"
] | Telithromycin | Cabozantinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1056,
25,
1618
]
],
[
[
1056,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
1056,
62,
112
],
[
112,
23,
1618
]
],
[
[
1056,
63,
723
],
[
723,
... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Telithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole ma... |
DB00056 | DB11817 | 816 | 1,259 | [
"DDInter814",
"DDInter165"
] | Gemtuzumab ozogamicin | Baricitinib | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
816,
25,
1259
]
],
[
[
816,
24,
949
],
[
949,
24,
1259
]
],
[
[
816,
24,
1129
],
[
1129,
63,
1259
]
],
[
[
816,
24,
384
],
[
384,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani ... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
... |
DB00850 | DB00927 | 1,630 | 1,559 | [
"DDInter1432",
"DDInter712"
] | Perphenazine | Famotidine | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1630,
24,
1559
]
],
[
[
1630,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
1630,
18,
1918
],
[
1918,
57,
1559
]
],
[
[
1630,
21,
28826
],
[
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compo... | Perphenazine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Perphenazine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Famotidine (Compound)
Perphenazine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound... |
DB00783 | DB09045 | 1,438 | 52 | [
"DDInter679",
"DDInter607"
] | Estradiol | Dulaglutide | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1438,
24,
52
]
],
[
[
1438,
24,
170
],
[
170,
23,
52
]
],
[
[
1438,
24,
609
],
[
609,
24,
52
]
],
[
[
1438,
63,
870
],
[
870,
24... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cla... |
DB08870 | DB09074 | 850 | 1,362 | [
"DDInter228",
"DDInter1327"
] | Brentuximab vedotin | Olaparib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
850,
24,
1362
]
],
[
[
850,
24,
725
],
[
725,
63,
1362
]
],
[
[
850,
63,
896
],
[
896,
24,
1362
]
],
[
[
850,
24,
250
],
[
250,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizuma... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with E... |
DB00497 | DB09054 | 828 | 384 | [
"DDInter1366",
"DDInter905"
] | Oxycodone | Idelalisib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
828,
25,
384
]
],
[
[
828,
24,
222
],
[
222,
23,
384
]
],
[
[
828,
63,
58
],
[
58,
24,
384
]
],
[
[
828,
64,
600
],
[
600,
24,
... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept... |
DB01156 | DB01165 | 593 | 1,539 | [
"DDInter252",
"DDInter1325"
] | Bupropion | Ofloxacin | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Major | 2 | [
[
[
593,
25,
1539
]
],
[
[
593,
64,
1467
],
[
1467,
1,
1539
]
],
[
[
593,
25,
945
],
[
945,
40,
1539
]
],
[
[
593,
64,
956
],
[
956,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compoun... | Bupropion may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Bupropion may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Bupropion may lead to a major life... |
DB00341 | DB00748 | 1,242 | 662 | [
"DDInter343",
"DDInter297"
] | Cetirizine | Carbinoxamine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
1242,
24,
662
]
],
[
[
1242,
24,
1594
],
[
1594,
24,
662
]
],
[
[
1242,
40,
465
],
[
465,
40,
662
]
],
[
[
1242,
6,
10104
],
[
10104,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Cetirizine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Carbinoxami... |
DB01064 | DB01222 | 1,148 | 617 | [
"DDInter987",
"DDInter246"
] | Isoprenaline | Budesonide | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Minor | 0 | [
[
[
1148,
23,
617
]
],
[
[
1148,
62,
1351
],
[
1351,
1,
617
]
],
[
[
1148,
23,
1220
],
[
1220,
1,
617
]
],
[
[
1148,
5,
11649
],
[
11649,
... | [
[
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flunisolide"
],
[
... | Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Co... |
DB00595 | DB14761 | 1,545 | 242 | [
"DDInter1374",
"DDInter1578"
] | Oxytetracycline | Remdesivir | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1545,
24,
242
]
],
[
[
1545,
24,
384
],
[
384,
24,
242
]
],
[
[
1545,
25,
1517
],
[
1517,
24,
242
]
],
[
[
1545,
64,
640
],
[
640,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Oxytetracycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretin... |
DB06448 | DB11921 | 171 | 1,019 | [
"DDInter1087",
"DDInter492"
] | Lonafarnib | Deflazacort | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
171,
25,
1019
]
],
[
[
171,
25,
1619
],
[
1619,
63,
1019
]
],
[
[
171,
63,
1411
],
[
1411,
24,
1019
]
],
[
[
171,
64,
629
],
[
629,
... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} ma... | Lonafarnib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause... |
DB00390 | DB01234 | 1,252 | 1,220 | [
"DDInter554",
"DDInter513"
] | Digoxin | Dexamethasone | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1252,
24,
1220
]
],
[
[
1252,
24,
870
],
[
870,
1,
1220
]
],
[
[
1252,
24,
175
],
[
175,
40,
1220
]
],
[
[
1252,
6,
10083
],
[
10083,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexametha... |
DB00738 | DB01059 | 485 | 956 | [
"DDInter1420",
"DDInter1313"
] | Pentamidine | Norfloxacin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Moderate | 1 | [
[
[
485,
24,
956
]
],
[
[
485,
24,
872
],
[
872,
40,
956
]
],
[
[
485,
64,
1176
],
[
1176,
1,
956
]
],
[
[
485,
24,
1539
],
[
1539,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Pentamidine may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Pen... |
DB00035 | DB00533 | 1,314 | 1,416 | [
"DDInter507",
"DDInter1613"
] | Desmopressin | Rofecoxib | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Moderate | 1 | [
[
[
1314,
24,
1416
]
],
[
[
1314,
25,
167
],
[
167,
63,
1416
]
],
[
[
1314,
24,
848
],
[
848,
63,
1416
]
],
[
[
1314,
23,
1479
],
[
1479,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hyd... | Desmopressin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen m... |
DB00087 | DB09036 | 599 | 812 | [
"DDInter41",
"DDInter1668"
] | Alemtuzumab | Siltuximab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
599,
24,
812
]
],
[
[
599,
24,
287
],
[
287,
63,
812
]
],
[
[
599,
24,
1430
],
[
1430,
24,
812
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Sip... |
DB00197 | DB06448 | 1,324 | 171 | [
"DDInter1881",
"DDInter1087"
] | Troglitazone | Lonafarnib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
1324,
24,
171
]
],
[
[
1324,
24,
222
],
[
222,
23,
171
]
],
[
[
1324,
24,
1601
],
[
1601,
24,
171
]
],
[
[
1324,
24,
310
],
[
310,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Lo... |
DB01035 | DB01362 | 1,401 | 497 | [
"DDInter1524",
"DDInter960"
] | Procainamide | Iohexol | A derivative of procaine with less CNS action. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
1401,
24,
497
]
],
[
[
1401,
24,
258
],
[
258,
40,
497
]
],
[
[
1401,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1401,
25,
1264
],
[
1264,... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
... | Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Procainamide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Procainamide may lead to a major l... |
DB00342 | DB00983 | 1,181 | 480 | [
"DDInter1770",
"DDInter776"
] | Terfenadine | Formoterol | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1181,
24,
480
]
],
[
[
1181,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1181,
25,
932
],
[
932,
24,
480
]
],
[
[
1181,
25,
868
],
[
868,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Terfenadine may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone ... |
DB00515 | DB12615 | 589 | 1,381 | [
"DDInter387",
"DDInter1482"
] | Cisplatin | Plazomicin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Moderate | 1 | [
[
[
589,
24,
1381
]
],
[
[
589,
24,
101
],
[
101,
24,
1381
]
],
[
[
589,
63,
837
],
[
837,
24,
1381
]
],
[
[
589,
25,
777
],
[
777,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole ... |
DB05812 | DB06402 | 1,374 | 1,079 | [
"DDInter8",
"DDInter1756"
] | Abiraterone | Telavancin | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
1374,
24,
1079
]
],
[
[
1374,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
1374,
62,
112
],
[
112,
23,
1079
]
],
[
[
1374,
24,
657
],
[
657... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Abiraterone",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v... | Abiraterone (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Ab... |
DB01234 | DB08865 | 1,220 | 1,593 | [
"DDInter513",
"DDInter448"
] | Dexamethasone | Crizotinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1220,
24,
1593
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1220,
18,
7580
],
[
7580,
45,
1593
]
],
[
[
1220,
7,
2900
],
[
2900... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Dexamethasone (Compound) downregulates TESK1 (Gene) and TESK1 (Gene) is bound by Crizotinib (Compound)
Dexamethasone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Crizotinib (Compound)
Dexamethaso... |
DB00372 | DB00992 | 999 | 842 | [
"DDInter1793",
"DDInter1182"
] | Thiethylperazine | Methyl aminolevulinate (topical) | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
999,
24,
842
]
],
[
[
999,
24,
612
],
[
612,
24,
842
]
],
[
[
999,
24,
504
],
[
504,
63,
842
]
],
[
[
999,
63,
1028
],
[
1028,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ver... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin and Verteporfin may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00682 | DB00978 | 126 | 739 | [
"DDInter1951",
"DDInter1084"
] | Warfarin | Lomefloxacin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Major | 2 | [
[
[
126,
25,
739
]
],
[
[
126,
25,
945
],
[
945,
40,
739
]
],
[
[
126,
64,
1176
],
[
1176,
1,
739
]
],
[
[
126,
64,
1467
],
[
1467,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u}... | Warfarin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Warfarin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Warfarin may lead to a... |
DB00065 | DB00601 | 581 | 453 | [
"DDInter923",
"DDInter1073"
] | Infliximab | Linezolid | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Major | 2 | [
[
[
581,
25,
453
]
],
[
[
581,
24,
792
],
[
792,
1,
453
]
],
[
[
581,
25,
770
],
[
770,
63,
453
]
],
[
[
581,
24,
10
],
[
10,
24,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Linezolid"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaba... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban (Compound) resembles Linezolid (Compound)
Infliximab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate ... |
DB00637 | DB09472 | 1,557 | 1,383 | [
"DDInter128",
"DDInter1693"
] | Astemizole | Sodium sulfate | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Major | 2 | [
[
[
1557,
25,
1383
]
],
[
[
1557,
25,
609
],
[
609,
24,
1383
]
],
[
[
1557,
63,
521
],
[
521,
24,
1383
]
],
[
[
1557,
24,
371
],
[
371,
... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
... | Astemizole may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin ... |
DB00347 | DB11988 | 917 | 270 | [
"DDInter1871",
"DDInter1321"
] | Trimethadione | Ocrelizumab | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
917,
24,
270
]
],
[
[
917,
24,
770
],
[
770,
24,
270
]
],
[
[
917,
63,
599
],
[
599,
24,
270
]
],
[
[
917,
64,
1064
],
[
1064,
2... | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
... | Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab ... |
DB04908 | DB06282 | 1,671 | 516 | [
"DDInter741",
"DDInter1053"
] | Flibanserin | Levocetirizine | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1671,
24,
516
]
],
[
[
1671,
63,
701
],
[
701,
24,
516
]
],
[
[
1671,
24,
407
],
[
407,
63,
516
]
],
[
[
1671,
64,
543
],
[
543,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium... |
DB00011 | DB00995 | 1,451 | 1,112 | [
"DDInter944",
"DDInter139"
] | Interferon alfa-n1 | Auranofin | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Moderate | 1 | [
[
[
1451,
24,
1112
]
],
[
[
1451,
24,
36
],
[
36,
63,
1112
]
],
[
[
1451,
24,
134
],
[
134,
24,
1112
]
],
[
[
1451,
63,
491
],
[
491,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Auranofin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbin... |
DB01045 | DB09143 | 463 | 313 | [
"DDInter1590",
"DDInter1701"
] | Rifampicin | Sonidegib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
463,
25,
313
]
],
[
[
463,
63,
837
],
[
837,
23,
313
]
],
[
[
463,
24,
101
],
[
101,
23,
313
]
],
[
[
463,
25,
478
],
[
478,
24,... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantopraz... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and ... |
DB06288 | DB08875 | 607 | 1,618 | [
"DDInter77",
"DDInter262"
] | Amisulpride | Cabozantinib | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
607,
25,
1618
]
],
[
[
607,
62,
112
],
[
112,
23,
1618
]
],
[
[
607,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
607,
63,
480
],
[
480,
... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Amisulpride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric ac... |
DB00682 | DB08860 | 126 | 788 | [
"DDInter1951",
"DDInter1479"
] | Warfarin | Pitavastatin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Minor | 0 | [
[
[
126,
23,
788
]
],
[
[
126,
23,
671
],
[
671,
1,
788
]
],
[
[
126,
23,
700
],
[
700,
40,
788
]
],
[
[
126,
6,
3486
],
[
3486,
45,... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pitavastatin"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluvastatin"
],
[
"... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Compound... |
DB00535 | DB00682 | 1,145 | 126 | [
"DDInter315",
"DDInter1951"
] | Cefdinir | Warfarin | Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat ... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1145,
24,
126
]
],
[
[
1145,
63,
597
],
[
597,
24,
126
]
],
[
[
1145,
1,
731
],
[
731,
63,
126
]
],
[
[
1145,
1,
1087
],
[
1087,
... | [
[
[
"Cefdinir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Cefdinir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
... | Cefdinir may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Cefdinir (Compound) resembles Ceftizoxime (Compound) and Ceftizoxime may cause a moderate interaction that... |
DB01319 | DB06335 | 34 | 761 | [
"DDInter777",
"DDInter1646"
] | Fosamprenavir | Saxagliptin | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
34,
24,
761
]
],
[
[
34,
6,
8374
],
[
8374,
45,
761
]
],
[
[
34,
21,
28722
],
[
28722,
60,
761
]
],
[
[
34,
24,
1491
],
[
1491,
... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Fosamprenavir (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin an... |
DB00738 | DB09080 | 485 | 144 | [
"DDInter1420",
"DDInter1331"
] | Pentamidine | Olodaterol | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
485,
24,
144
]
],
[
[
485,
23,
1247
],
[
1247,
23,
144
]
],
[
[
485,
24,
956
],
[
956,
24,
144
]
],
[
[
485,
25,
1011
],
[
1011,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin... |
DB00554 | DB01099 | 1,027 | 1,272 | [
"DDInter1478",
"DDInter744"
] | Piroxicam | Flucytosine | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
1027,
24,
1272
]
],
[
[
1027,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
1027,
24,
712
],
[
712,
63,
1272
]
],
[
[
1027,
40,
1171
],
[
1171... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Ols... |
DB00939 | DB09075 | 1,338 | 498 | [
"DDInter1135",
"DDInter621"
] | Meclofenamic acid | Edoxaban | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1338,
25,
498
]
],
[
[
1338,
24,
222
],
[
222,
24,
498
]
],
[
[
1338,
24,
738
],
[
738,
63,
498
]
],
[
[
1338,
63,
305
],
[
305,
... | [
[
[
"Meclofenamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Nirapar... |
DB00208 | DB01254 | 1,018 | 1,213 | [
"DDInter1804",
"DDInter484"
] | Ticlopidine | Dasatinib | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
1018,
25,
1213
]
],
[
[
1018,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
1018,
18,
10375
],
[
10375,
57,
1213
]
],
[
[
1018,
21,
28882
],
[
... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasati... | Ticlopidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Ticlopidine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Dasatinib (Compound)
Ticlopidine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) ... |
DB08881 | DB11760 | 868 | 119 | [
"DDInter1925",
"DDInter1742"
] | Vemurafenib | Talazoparib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
868,
24,
119
]
],
[
[
868,
63,
441
],
[
441,
24,
119
]
],
[
[
868,
25,
985
],
[
985,
24,
119
]
],
[
[
868,
25,
1339
],
[
1339,
6... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
],
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Vemurafenib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may... |
DB00775 | DB11793 | 1,226 | 738 | [
"DDInter1818",
"DDInter1297"
] | Tirofiban | Niraparib | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1226,
24,
738
]
],
[
[
1226,
25,
1213
],
[
1213,
24,
738
]
],
[
[
1226,
64,
1578
],
[
1578,
24,
738
]
],
[
[
1226,
24,
848
],
[
848,
... | [
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Tirofiban may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tirofiban may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction... |
DB00619 | DB00762 | 1,419 | 613 | [
"DDInter909",
"DDInter973"
] | Imatinib | Irinotecan | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Moderate | 1 | [
[
[
1419,
24,
613
]
],
[
[
1419,
24,
869
],
[
869,
63,
613
]
],
[
[
1419,
5,
11555
],
[
11555,
44,
613
]
],
[
[
1419,
6,
8374
],
[
8374,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Irinotecan (C... |
DB00564 | DB01041 | 1,236 | 770 | [
"DDInter293",
"DDInter1789"
] | Carbamazepine | Thalidomide | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1236,
24,
770
]
],
[
[
1236,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1236,
21,
28789
],
[
28789,
60,
770
]
],
[
[
1236,
25,
609
],
[
609,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Comp... | Carbamazepine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Carbamazepine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Carbamazepine may lead to a major life threatening interaction when taken with... |
DB00065 | DB01285 | 581 | 708 | [
"DDInter923",
"DDInter445"
] | Infliximab | Corticotropin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Major | 2 | [
[
[
581,
25,
708
]
],
[
[
581,
24,
126
],
[
126,
24,
708
]
],
[
[
581,
24,
1136
],
[
1136,
63,
708
]
],
[
[
581,
64,
1184
],
[
1184,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin"... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosuma... |
DB00092 | DB00526 | 58 | 1,555 | [
"DDInter40",
"DDInter1355"
] | Alefacept | Oxaliplatin | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
58,
24,
1555
]
],
[
[
58,
24,
141
],
[
141,
24,
1555
]
],
[
[
58,
24,
1136
],
[
1136,
63,
1555
]
],
[
[
58,
63,
305
],
[
305,
24... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosu... |
DB00401 | DB00470 | 84 | 530 | [
"DDInter1298",
"DDInter601"
] | Nisoldipine | Dronabinol | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
84,
24,
530
]
],
[
[
84,
24,
1614
],
[
1614,
40,
530
]
],
[
[
84,
6,
4973
],
[
4973,
45,
530
]
],
[
[
84,
21,
29226
],
[
29226,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Nisoldipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dronabinol (Compound)
Nisoldipine (Compound) causes Sinusitis (Side Effect) and Sinusitis (S... |
DB06228 | DB11581 | 792 | 1,456 | [
"DDInter1609",
"DDInter1926"
] | Rivaroxaban | Venetoclax | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
792,
24,
1456
]
],
[
[
792,
63,
536
],
[
536,
24,
1456
]
],
[
[
792,
24,
259
],
[
259,
24,
1456
]
],
[
[
792,
24,
241
],
[
241,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and ... |
DB00853 | DB10429 | 1,686 | 200 | [
"DDInter1762",
"DDInter282"
] | Temozolomide | Candida albicans | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1686,
24,
200
]
],
[
[
1686,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1686,
25,
976
],
[
976,
24,
200
]
],
[
[
1686,
63,
147
],
[
147,
... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Temozolomide may lead to a major life threatening interaction when taken with Tofacitinib and Tofaciti... |
DB00367 | DB08904 | 566 | 375 | [
"DDInter1061",
"DDInter342"
] | Levonorgestrel | Certolizumab pegol | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
566,
24,
375
]
],
[
[
566,
1,
1336
],
[
1336,
24,
375
]
],
[
[
566,
23,
14
],
[
14,
24,
375
]
],
[
[
566,
63,
58
],
[
58,
24,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u}... | Levonorgestrel (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Levonorgestrel may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a moderate ... |
DB00731 | DB01261 | 1,144 | 170 | [
"DDInter1269",
"DDInter1679"
] | Nateglinide | Sitagliptin | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1144,
24,
170
]
],
[
[
1144,
5,
11640
],
[
11640,
44,
170
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
170
]
],
[
[
1144,
21,
28850
],
[
2885... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Nateglinide",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
... | Nateglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Nateglinide (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) i... |
DB00574 | DB00712 | 121 | 1,274 | [
"DDInter717",
"DDInter763"
] | Fenfluramine | Flurbiprofen | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
121,
24,
1274
]
],
[
[
121,
24,
935
],
[
935,
63,
1274
]
],
[
[
121,
23,
479
],
[
479,
62,
1274
]
],
[
[
121,
64,
529
],
[
529,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Don... |
DB01166 | DB04953 | 477 | 495 | [
"DDInter379",
"DDInter708"
] | Cilostazol | Ezogabine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
477,
24,
495
]
],
[
[
477,
21,
28997
],
[
28997,
60,
495
]
],
[
[
477,
62,
112
],
[
112,
23,
495
]
],
[
[
477,
63,
1494
],
[
1494,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Cilostazol",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} ... | Cilostazol (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects ... |
DB00083 | DB00372 | 677 | 999 | [
"DDInter225",
"DDInter1793"
] | Botulinum toxin type A | Thiethylperazine | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
677,
24,
999
]
],
[
[
677,
24,
352
],
[
352,
24,
999
]
],
[
[
677,
24,
100
],
[
100,
63,
999
]
],
[
[
677,
24,
352
],
[
352,
24,... | [
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken ... |
DB05812 | DB09049 | 1,374 | 1,135 | [
"DDInter8",
"DDInter1261"
] | Abiraterone | Naloxegol | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
1374,
23,
1135
]
],
[
[
1374,
64,
33
],
[
33,
23,
1135
]
],
[
[
1374,
63,
495
],
[
495,
23,
1135
]
],
[
[
1374,
24,
971
],
[
971,
... | [
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone"... | Abiraterone may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine may cause a m... |
DB00776 | DB06228 | 1,335 | 792 | [
"DDInter1360",
"DDInter1609"
] | Oxcarbazepine | Rivaroxaban | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
1335,
24,
792
]
],
[
[
1335,
6,
7524
],
[
7524,
45,
792
]
],
[
[
1335,
7,
2384
],
[
2384,
46,
792
]
],
[
[
1335,
21,
28703
],
[
28703,... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Comp... | Oxcarbazepine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Rivaroxaban (Compound)
Oxcarbazepine (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Rivaroxaban (Compound)
Oxcarbazepine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound... |
DB00220 | DB01278 | 798 | 1,021 | [
"DDInter1276",
"DDInter1506"
] | Nelfinavir | Pramlintide | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
798,
24,
1021
]
],
[
[
798,
24,
1142
],
[
1142,
24,
1021
]
],
[
[
798,
25,
1019
],
[
1019,
63,
1021
]
],
[
[
798,
24,
850
],
[
850,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
],
[
... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Nelfinavir may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a... |
DB00827 | DB06335 | 646 | 761 | [
"DDInter383",
"DDInter1646"
] | Cinoxacin | Saxagliptin | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
646,
24,
761
]
],
[
[
646,
21,
28722
],
[
28722,
60,
761
]
],
[
[
646,
64,
1573
],
[
1573,
24,
761
]
],
[
[
646,
25,
1296
],
[
1296,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Cinoxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Cinoxacin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Cinoxacin may lead to a major life threatening interaction when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Cinoxacin may lea... |
DB00092 | DB15035 | 58 | 503 | [
"DDInter40",
"DDInter1959"
] | Alefacept | Zanubrutinib | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
58,
24,
503
]
],
[
[
58,
24,
1430
],
[
1430,
24,
503
]
],
[
[
58,
63,
599
],
[
599,
24,
503
]
],
[
[
58,
24,
39
],
[
39,
25,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and A... |
DB00424 | DB00835 | 19 | 100 | [
"DDInter896",
"DDInter245"
] | Hyoscyamine | Brompheniramine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
19,
24,
100
]
],
[
[
19,
24,
832
],
[
832,
24,
100
]
],
[
[
19,
63,
508
],
[
508,
24,
100
]
],
[
[
19,
24,
211
],
[
211,
63,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Promaz... |
DB00863 | DB11828 | 1,194 | 1,406 | [
"DDInter1568",
"DDInter1281"
] | Ranitidine | Neratinib | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
1194,
25,
1406
]
],
[
[
1194,
24,
392
],
[
392,
24,
1406
]
],
[
[
1194,
23,
1117
],
[
1117,
24,
1406
]
],
[
[
1194,
63,
1195
],
[
1195... | [
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
... | Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sod... |
DB01068 | DB06723 | 1,565 | 115 | [
"DDInter411",
"DDInter58"
] | Clonazepam | Aluminum hydroxide | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
1565,
23,
115
]
],
[
[
1565,
21,
28643
],
[
28643,
60,
115
]
],
[
[
1565,
40,
523
],
[
523,
23,
115
]
],
[
[
1565,
1,
1418
],
[
1418,
... | [
[
[
"Clonazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Clonazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) i... | Clonazepam (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Clonazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Clonazepam (Compound) resemble... |
DB00264 | DB06603 | 88 | 39 | [
"DDInter1200",
"DDInter1387"
] | Metoprolol | Panobinostat | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
88,
24,
39
]
],
[
[
88,
24,
455
],
[
455,
24,
39
]
],
[
[
88,
23,
578
],
[
578,
63,
39
]
],
[
[
88,
24,
144
],
[
144,
63,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagr... |
DB00342 | DB06788 | 1,181 | 1,616 | [
"DDInter1770",
"DDInter864"
] | Terfenadine | Histrelin | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1181,
24,
1616
]
],
[
[
1181,
23,
112
],
[
112,
23,
1616
]
],
[
[
1181,
24,
1664
],
[
1664,
24,
1616
]
],
[
[
1181,
24,
603
],
[
603,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Ri... |
DB00427 | DB05381 | 1,233 | 172 | [
"DDInter1879",
"DDInter863"
] | Triprolidine | Histamine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
1233,
24,
172
]
],
[
[
1233,
24,
1264
],
[
1264,
24,
172
]
],
[
[
1233,
63,
1242
],
[
1242,
24,
172
]
],
[
[
1233,
24,
337
],
[
337,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizin... |
DB09078 | DB09268 | 1,228 | 1,662 | [
"DDInter1036",
"DDInter1464"
] | Lenvatinib | Picosulfuric acid | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1228,
24,
1662
]
],
[
[
1228,
63,
1164
],
[
1164,
24,
1662
]
],
[
[
1228,
24,
484
],
[
484,
63,
1662
]
],
[
[
1228,
64,
1618
],
[
1618... | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],... | Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Entrectini... |
DB00813 | DB04837 | 704 | 649 | [
"DDInter722",
"DDInter407"
] | Fentanyl | Clofedanol | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
704,
24,
649
]
],
[
[
704,
35,
1376
],
[
1376,
24,
649
]
],
[
[
704,
1,
675
],
[
675,
40,
649
]
],
[
[
704,
63,
832
],
[
832,
40... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Fentanyl (Compound) resembles Diphenhydramine (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Fentanyl (Compound) resembles Dextropropoxy... |
DB00280 | DB08820 | 494 | 1,478 | [
"DDInter575",
"DDInter997"
] | Disopyramide | Ivacaftor | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
494,
24,
1478
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
494,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
494,
24,
543
],
[
543,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Disopyramide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lo... |
DB00762 | DB04834 | 613 | 276 | [
"DDInter973",
"DDInter1571"
] | Irinotecan | Rapacuronium | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm. | Minor | 0 | [
[
[
613,
23,
276
]
],
[
[
613,
24,
1220
],
[
1220,
24,
276
]
],
[
[
613,
6,
8374
],
[
8374,
45,
1194
],
[
1194,
23,
276
]
],
[
[
613,
... | [
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rapacuronium"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Rapacuronium
Irinotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ranitidine (Compound) and Raniti... |
DB00626 | DB00728 | 1,441 | 1,610 | [
"DDInter161",
"DDInter1612"
] | Bacitracin | Rocuronium | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Moderate | 1 | [
[
[
1441,
24,
1610
]
],
[
[
1441,
24,
728
],
[
728,
40,
1610
]
],
[
[
1441,
21,
28722
],
[
28722,
60,
1610
]
],
[
[
1441,
63,
91
],
[
91,
... | [
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
],
[
... | Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Bacitracin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Rocuronium (Compound)
Bacitracin may cause a moderate interaction that c... |
DB00222 | DB00465 | 245 | 886 | [
"DDInter825",
"DDInter1010"
] | Glimepiride | Ketorolac | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Moderate | 1 | [
[
[
245,
24,
886
]
],
[
[
245,
24,
24
],
[
24,
40,
886
]
],
[
[
245,
21,
28936
],
[
28936,
60,
886
]
],
[
[
245,
24,
752
],
[
752,
6... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) resembles Ketorolac (Compound)
Glimepiride (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Ketorolac (Compound)
Glimepiride may cause a moderate interac... |
DB00647 | DB08895 | 675 | 976 | [
"DDInter528",
"DDInter1825"
] | Dextropropoxyphene | Tofacitinib | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
675,
24,
976
]
],
[
[
675,
40,
307
],
[
307,
23,
976
]
],
[
[
675,
25,
982
],
[
982,
63,
976
]
],
[
[
675,
40,
998
],
[
998,
24,... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may ... | Dextropropoxyphene (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Dextropropoxyphene may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could e... |
DB00414 | DB01165 | 590 | 1,539 | [
"DDInter16",
"DDInter1325"
] | Acetohexamide | Ofloxacin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Major | 2 | [
[
[
590,
25,
1539
]
],
[
[
590,
64,
1176
],
[
1176,
1,
1539
]
],
[
[
590,
25,
956
],
[
956,
40,
1539
]
],
[
[
590,
25,
246
],
[
246,
... | [
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
]
],
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
... | Acetohexamide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Acetohexamide may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin (Compound) resembles Ofloxacin (Compound)
Acetohexamide may le... |
DB00679 | DB11718 | 684 | 927 | [
"DDInter1796",
"DDInter640"
] | Thioridazine | Encorafenib | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
684,
25,
927
]
],
[
[
684,
23,
112
],
[
112,
23,
927
]
],
[
[
684,
24,
720
],
[
720,
24,
927
]
],
[
[
684,
40,
216
],
[
216,
24,... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Thioridazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Thioridazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil an... |
DB06788 | DB14881 | 1,616 | 180 | [
"DDInter864",
"DDInter1329"
] | Histrelin | Oliceridine | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1616,
24,
180
]
],
[
[
1616,
62,
112
],
[
112,
23,
180
]
],
[
[
1616,
63,
401
],
[
401,
24,
180
]
],
[
[
1616,
24,
124
],
[
124,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Histrelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pro... |
DB00390 | DB09481 | 1,252 | 460 | [
"DDInter554",
"DDInter1113"
] | Digoxin | Magnesium carbonate | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
1252,
23,
460
]
],
[
[
1252,
23,
752
],
[
752,
23,
460
]
],
[
[
1252,
62,
1018
],
[
1018,
23,
460
]
],
[
[
1252,
24,
1468
],
[
1468,
... | [
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
... | Digoxin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Digoxin may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopid... |
DB00622 | DB11130 | 1,081 | 407 | [
"DDInter1287",
"DDInter1344"
] | Nicardipine | Opium | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1081,
24,
407
]
],
[
[
1081,
40,
409
],
[
409,
24,
407
]
],
[
[
1081,
24,
104
],
[
104,
24,
407
]
],
[
[
1081,
63,
1648
],
[
1648,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate i... | Nicardipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that coul... |
DB00978 | DB01592 | 739 | 1,596 | [
"DDInter1084",
"DDInter975"
] | Lomefloxacin | Iron | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Moderate | 1 | [
[
[
739,
24,
1596
]
],
[
[
739,
21,
29024
],
[
29024,
60,
1596
]
],
[
[
739,
24,
1193
],
[
1193,
62,
1596
]
],
[
[
739,
24,
1096
],
[
1096... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is ... | Lomefloxacin (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Iron (Compound)
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken wi... |
DB00685 | DB01276 | 1,299 | 123 | [
"DDInter1887",
"DDInter706"
] | Trovafloxacin | Exenatide | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1299,
24,
123
]
],
[
[
1299,
64,
1573
],
[
1573,
24,
123
]
],
[
[
1299,
63,
1560
],
[
1560,
24,
123
]
],
[
[
1299,
25,
1220
],
[
1220,... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Predn... | Trovafloxacin may lead to a major life threatening interaction when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase m... |
DB00393 | DB06372 | 854 | 259 | [
"DDInter1295",
"DDInter1594"
] | Nimodipine | Rilonacept | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
854,
24,
259
]
],
[
[
854,
24,
1619
],
[
1619,
63,
259
]
],
[
[
854,
24,
478
],
[
478,
24,
259
]
],
[
[
854,
1,
409
],
[
409,
24... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib... |
DB00384 | DB01285 | 1,275 | 708 | [
"DDInter1859",
"DDInter445"
] | Triamterene | Corticotropin | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1275,
24,
708
]
],
[
[
1275,
24,
123
],
[
123,
24,
708
]
],
[
[
1275,
24,
1662
],
[
1662,
63,
708
]
],
[
[
1275,
63,
1645
],
[
1645,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid ... |
DB00381 | DB12141 | 376 | 971 | [
"DDInter79",
"DDInter817"
] | Amlodipine | Gilteritinib | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
376,
24,
971
]
],
[
[
376,
23,
466
],
[
466,
62,
971
]
],
[
[
376,
24,
820
],
[
820,
24,
971
]
],
[
[
376,
24,
283
],
[
283,
63,... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Amlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Amlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Ali... |
DB00459 | DB05528 | 640 | 1,070 | [
"DDInter21",
"DDInter1228"
] | Acitretin | Mipomersen | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
640,
25,
1070
]
],
[
[
640,
25,
1517
],
[
1517,
25,
1070
]
],
[
[
640,
24,
384
],
[
384,
64,
1070
]
],
[
[
640,
64,
1101
],
[
1101,
... | [
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u}... | Acitretin may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Mipomersen
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major lif... |
DB00188 | DB12010 | 168 | 214 | [
"DDInter222",
"DDInter785"
] | Bortezomib | Fostamatinib | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
168,
24,
214
]
],
[
[
168,
25,
976
],
[
976,
24,
214
]
],
[
[
168,
24,
723
],
[
723,
24,
214
]
],
[
[
168,
23,
307
],
[
307,
24,... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacit... | Bortezomib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may ca... |
DB00445 | DB00845 | 322 | 1,490 | [
"DDInter655",
"DDInter406"
] | Epirubicin | Clofazimine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Moderate | 1 | [
[
[
322,
24,
1490
]
],
[
[
322,
21,
28787
],
[
28787,
60,
1490
]
],
[
[
322,
23,
112
],
[
112,
62,
1490
]
],
[
[
322,
24,
1250
],
[
1250,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is c... | Epirubicin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Clofazimine (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cl... |
DB01001 | DB01166 | 688 | 477 | [
"DDInter1632",
"DDInter379"
] | Salbutamol | Cilostazol | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
688,
24,
477
]
],
[
[
688,
6,
8374
],
[
8374,
45,
477
]
],
[
[
688,
21,
28688
],
[
28688,
60,
477
]
],
[
[
688,
62,
112
],
[
112,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Salbutamol (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Cilostazol (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB06372 | DB06772 | 259 | 310 | [
"DDInter1594",
"DDInter259"
] | Rilonacept | Cabazitaxel | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
259,
24,
310
]
],
[
[
259,
63,
973
],
[
973,
24,
310
]
],
[
[
259,
24,
800
],
[
800,
63,
310
]
],
[
[
259,
24,
1430
],
[
1430,
2... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duveli... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.